Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
US Food and Drug Administration. FDA approves new drug treatment for high blood pressure [online], (2007).
Harel, Z. et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344, e42 (2012).
Gormley, K., Dong, Y. & Sagnella, G. A. Regulation of the epithelial sodium channel by accessory proteins. Biochem. J. 371, 1–14 (2003).
Toto, R. D., Mitchell, H. C., Lee, H. C., Milam, C. & Pettinger, W. A. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann. Intern. Med. 115, 513–519 (1991).
Mann, J. F. et al. for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151, 1–10 (2009).
Ting, R. Z., Luk, A. O. & Chan, J. C. Treatment and landmark clinical trials for renoprotection. Contrib. Nephrol. 170, 184–195 (2011).
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641–2650 (2009).
Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).
Oparil, S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221–229 (2007).
R. D. Toto is a consultant for and has received research funding from Novartis.
About this article
Cite this article
Toto, R. RAS blockade, hyperkalemia and AKI—look and you will find. Nat Rev Nephrol 8, 257–258 (2012). https://doi.org/10.1038/nrneph.2012.62
Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
American Journal of Kidney Diseases (2014)
Diabetes Care (2014)
Kidney and Blood Pressure Research (2012)